MDWD vs. URGN
MDWD (MediWound Ltd.) and URGN (UroGen Pharma Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, MDWD returned -16.63%/yr vs 15.31%/yr for URGN. At a 0.16 correlation, their price movements are largely independent.
Performance
MDWD vs. URGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDWD achieves a -23.78% return, which is significantly lower than URGN's 50.09% return.
MDWD
- 1D
- 0.79%
- 1M
- -15.14%
- YTD
- -23.78%
- 6M
- -24.92%
- 1Y
- -25.91%
- 3Y*
- 10.60%
- 5Y*
- -16.63%
- 10Y*
- -12.79%
URGN
- 1D
- 0.46%
- 1M
- 21.67%
- YTD
- 50.09%
- 6M
- 50.21%
- 1Y
- 145.80%
- 3Y*
- 45.29%
- 5Y*
- 15.31%
- 10Y*
- —
MDWD vs. URGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MDWD MediWound Ltd. | -23.78% | 3.71% | 75.02% | -24.61% | -18.34% | -36.22% | 19.35% | -23.65% | -8.76% | -26.45% |
URGN UroGen Pharma Ltd. | 50.09% | 119.91% | -29.00% | 69.11% | -6.73% | -47.23% | -46.00% | -22.50% | 15.72% | 179.98% |
Correlation
The correlation between MDWD and URGN is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since May 4, 2017 | 0.16 |
Fundamentals
MDWD:
$181.14M
URGN:
$1.76B
MDWD:
-$2.20
URGN:
-$2.73
MDWD:
11.55
URGN:
12.21
MDWD:
$14.48M
URGN:
$140.49M
MDWD:
$2.84M
URGN:
$126.24M
MDWD:
-$24.21M
URGN:
-$117.04M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDWD vs. URGN — Risk / Return Rank
MDWD
URGN
MDWD vs. URGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MediWound Ltd. (MDWD) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDWD | URGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.80 | ||
| Sortino ratioReturn per unit of downside risk | -3.47 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.33 | -0.41 |
| Calmar ratioReturn relative to maximum drawdown | -0.74 | 3.47 | -4.22 |
| Martin ratioReturn relative to average drawdown | -1.46 | 7.23 | -8.68 |
Loading charts...
Drawdowns
MDWD vs. URGN - Drawdown Comparison
The maximum MDWD drawdown since its inception was -94.35%, roughly equal to the maximum URGN drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for MDWD and URGN.
Loading charts...
Drawdown Indicators
| MDWD | URGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.35% | -93.98% | -0.37% |
Max Drawdown (1Y)Largest decline over 1 year | -34.90% | -42.22% | +7.32% |
Max Drawdown (3Y)Largest decline over 3 years | -38.26% | -82.64% | +44.38% |
Max Drawdown (5Y)Largest decline over 5 years | -82.04% | -82.64% | +0.60% |
Max Drawdown (10Y)Largest decline over 10 years | -87.58% | — | — |
Current DrawdownCurrent decline from peak | -88.93% | -46.20% | -42.73% |
Average DrawdownAverage peak-to-trough decline | -75.90% | -61.47% | -14.43% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.80% | 20.29% | -2.49% |
Volatility
MDWD vs. URGN - Volatility Comparison
MediWound Ltd. (MDWD) has a higher volatility of 17.57% compared to UroGen Pharma Ltd. (URGN) at 12.53%. This indicates that MDWD's price experiences larger fluctuations and is considered to be riskier than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDWD | URGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.57% | 12.53% | +5.04% |
Volatility (6M)Calculated over the trailing 6-month period | 31.03% | 43.81% | -12.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 41.99% | 67.25% | -25.26% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.66% | 91.62% | -30.96% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 60.79% | 79.41% | -18.62% |
Dividends
MDWD vs. URGN - Dividend Comparison
Neither MDWD nor URGN has paid dividends to shareholders.
Financials
MDWD vs. URGN - Financials Comparison
This section allows you to compare key financial metrics between MediWound Ltd. and UroGen Pharma Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MDWD and URGN have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDWD has higher volatility (17.57%) compared to URGN (12.53%). In terms of maximum drawdown, MDWD dropped -94.35% vs URGN's -93.98%.
URGN currently has the higher Sharpe Ratio (2.18 vs -0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDWD and URGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer